CompletedPhase 2ACTRN12612000552886

Coenzyme Q10 for Alleviation of the Fatigue of Post Polio Syndrome

Oral supplementation of polio survivors with Post Polio Syndrome or Late Effects of Polio by coenzyme Q10 for relief of their excessive fatigue, as measured by fatigue questionnaires.


Sponsor

Professor Marie Cooke

Enrollment

110 participants

Start Date

Nov 6, 2012

Study Type

Interventional

Conditions

Summary

The primary purpose of the clinical trial is to determine whether taking a 100 mg capsule of coenzyme Q10 daily for a period of two months can alleviate the excessive fatigue of Post Polio Syndrome or Late Effects of Polio. This will be tested in a randomised, double-blind, placebo-controlled trial at the Griffith Clinical Trials Unit. Fatigue will be assessed by two fatigue questionnaires to be filled out by the participants before the start of the trial (baseline) and after the two-month period of taking capsules. Coenzyme Q10 blood levels will also be determined to confirm compliance and to validate the findings. Statistical analysis of the questionnaires will be undertaken by a biostatistician.


Eligibility

Sex: Both males and femalesMin Age: 50 Yearss

Inclusion Criteria1

  • Polio survivors with Post Polio Syndrome or the Late Effects of Polio who attribute their excessive fatigue primarily to PPS/LEOP

Exclusion Criteria3

  • Diagnosis with another medical condition that may account for the excessive fatigue, e.g. diabetes, anaemia, thyroid deficiency or fibromyalgia.
  • Treatment with warfarin since CoQ10 can redcue its effectiveness.
  • Those already taking CoQ10 on a regular basis

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Oral supplementation by 100 mg capsule of CoQ10 daily for a period of 2 months

Oral supplementation by 100 mg capsule of CoQ10 daily for a period of 2 months


Locations(1)

NSW,QLD, Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12612000552886